MED29

MED29 (IXL) is a subunit of the multi-subunit Mediator transcriptional coactivator complex that modulates RNA polymerase II–dependent transcription in a promoter- and activator-selective manner (PMID:15555573, PMID:15175162). As part of the endogenous CRSP/Mediator complex, it contributes to a combinatorial assembly in which subunit composition dictates which activators the complex can support, retaining coactivator function with VP16, Sp1, and SREBP-1a on chromatin templates (PMID:15175162); in isolation as a Gal4 fusion, MED29 acts as a context-dependent transcriptional suppressor and dampens SRE- and AP-1-driven, MAPK-responsive transcription (PMID:15555573). MED29 is required for neuronal development and migration: biallelic loss-of-function variants cause pontocerebellar hypoplasia with cataracts in humans, and depletion produces cerebellar GABAergic neuron, neurite outgrowth, and neuronal migration defects across zebrafish and mouse models with wild-type rescue (PMID:40745490). In cancer, MED29 has context-dependent roles—it is amplified at 19q13 and required for survival of amplified pancreatic cancer cells (PMID:17332321), yet behaves as both an oncogenic driver of EMT, migration, and invasion downstream of MAPK signaling and a tumor suppressor depending on cellular context (PMID:21225629, PMID:39462350), and its transcription is upregulated through HSPB1-dependent histone modification and ELK4 binding at its promoter (PMID:35526007).

1. 2004 Medium

   Establishing MED29 as a Mediator subunit and asking what it does to transcription positioned it as a context-dependent regulator rather than a generic coactivator.

   Evidence Gal4 fusion repression assays and SRE/AP-1 reporter assays in COS-7 cells with subcellular fractionation

   PMID:15555573

   Open questions at the time

   • No structural placement within Mediator
   • Suppressor activity inferred from overexpression/fusion, not endogenous complex behavior
2. 2004 High

   Structural and biochemical dissection of the CRSP/Mediator complex showed that subunit composition governs activator selectivity, framing how individual subunits like MED29 confer promoter specificity.

   Evidence Biochemical purification, EM single-particle reconstruction at 31 Å, and in vitro transcription on chromatin templates with multiple activators

   PMID:15175162

   Open questions at the time

   • MED29's specific contribution to the complex not isolated
   • Does not define MED29 contact surfaces or activator interactions directly
3. 2007 Medium

   The question of whether 19q13 amplification creates a dependency was answered by showing MED29 is selectively required for survival of amplified cancer cells.

   Evidence FISH copy number, RNAi knockdown, viability/cell cycle/apoptosis readouts in paired amplified (PANC-1) and non-amplified (MiaPaCa-2) lines

   PMID:17332321

   Open questions at the time

   • Transcriptional targets mediating survival dependency unidentified
   • Single lab, single tumor type
4. 2011 Medium

   Opposing knockdown and overexpression phenotypes resolved that MED29 has context-dependent oncogenic and tumor-suppressive roles rather than a single directional effect.

   Evidence RNAi knockdown, lentiviral overexpression, subcutaneous xenografts, and gene expression microarrays in pancreatic and fibroblast lines

   PMID:21225629

   Open questions at the time

   • Molecular basis of context-dependence not defined
   • Cell cycle gene changes correlative, not mechanistically linked
5. 2022 Medium

   Identifying how MED29 is transcriptionally upregulated revealed two converging regulatory axes controlling its expression in lung cancer.

   Evidence ChIP, luciferase reporters, RNA pulldown/MS, RIP, Co-IP, and gain/loss-of-function with in vivo tumor growth in NSCLC

   PMID:35526007

   Open questions at the time

   • Whether HSPB1 and ELK4 act independently or cooperatively unresolved
   • Downstream effectors of MED29 in proliferation/migration not mapped
6. 2024 Medium

   Linking MED29 to EMT downstream of MAPK signaling connected its transcriptional regulatory role to an invasive/metastatic program in solid tumors.

   Evidence Overexpression/knockdown with migration, invasion, and EMT readouts plus a tail-vein lung metastasis model, with CHRDL1/MAPK pathway manipulation in OSCC

   PMID:39462350

   Open questions at the time

   • MAPK link inferred from pathway inhibition, not direct biochemistry
   • Direct transcriptional targets driving EMT unidentified
7. 2025 High

   Human genetics combined with cross-species modeling established MED29 as essential for neuronal development and migration and as a cause of pontocerebellar hypoplasia.

   Evidence Whole-exome sequencing, zebrafish morpholino with WT rescue, mouse hippocampal shRNA neurite assays, and in utero electroporation migration assays; mutant overexpression

   PMID:40745490

   Open questions at the time

   • Neuronal transcriptional targets of MED29 unknown
   • How p.Leu139Pro disrupts Mediator function at the molecular level undefined
8. 2025 Low

   An invertebrate model raised the question of MED29's role in stem cell homeostasis, implicating it in germline stem cell number and germ cell apoptosis.

   Evidence Endogenous tagging/live imaging and germline-specific RNAi depletion in C. elegans (preprint)

   Open questions at the time

   • Preprint, single lab, not peer-reviewed
   • No mechanistic pathway placement for the germline phenotype
   • Conservation of this role in mammals untested

• The direct transcriptional targets and Mediator contacts through which MED29 exerts its context-dependent suppressor/coactivator activity across neurons and tumors remain undefined.
• No defined gene targets bridging MED29 to its developmental and oncogenic phenotypes
• No structural model of MED29 within Mediator